{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:51:47Z","timestamp":1775065907630,"version":"3.50.1"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40291-023-00654-1","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T17:02:06Z","timestamp":1684774926000},"page":"457-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders"],"prefix":"10.1007","volume":"27","author":[{"given":"Thuy Trang","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuong-Trang","family":"Nguyen-Thi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Hong Anh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh-Tam","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen-Minh-An","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toi","family":"Van Vo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-7865","authenticated-orcid":false,"given":"Giau","family":"Van Vo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"6571","key":"654_CR1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1126\/science.abl5163","volume":"374","author":"J Terreros-Roncal","year":"2021","unstructured":"Terreros-Roncal J, Moreno-Jim\u00e9nez EP, Flor-Garc\u00eda M, Rodr\u00edguez-Moreno CB, Trinchero MF, Cafini F, et al. Impact of neurodegenerative diseases on human adult hippocampal neurogenesis. Science. 2021;374(6571):1106\u201313.","journal-title":"Science"},{"issue":"4","key":"654_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","volume":"186","author":"DM Wilson","year":"2023","unstructured":"Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693\u2013714.","journal-title":"Cell"},{"issue":"6","key":"654_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"key":"654_CR4","doi-asserted-by":"publisher","first-page":"1270256","DOI":"10.1155\/2020\/1270256","volume":"2020","author":"G Cenini","year":"2020","unstructured":"Cenini G, Lloret A, Cascella R. Oxidative stress and mitochondrial damage in neurodegenerative diseases: from molecular mechanisms to targeted therapies. Oxidative Med Cell Longevity. 2020;2020:1270256.","journal-title":"Oxidative Med Cell Longevity"},{"key":"654_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2022.102270","volume":"214","author":"U Sengupta","year":"2022","unstructured":"Sengupta U, Kayed R. Amyloid \u03b2, Tau, and \u03b1-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol. 2022;214: 102270.","journal-title":"Prog Neurobiol"},{"issue":"2","key":"654_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/imm.12922","volume":"154","author":"J Stephenson","year":"2018","unstructured":"Stephenson J, Nutma E, van der Valk P, Amor S. Inflammation in CNS neurodegenerative diseases. Immunology. 2018;154(2):204\u201319.","journal-title":"Immunology"},{"issue":"1","key":"654_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-021-00276-9","volume":"11","author":"JC Zheng","year":"2022","unstructured":"Zheng JC, Chen S. Translational neurodegeneration in the era of fast growing international brain research. Transl Neurodegener. 2022;11(1):1.","journal-title":"Transl Neurodegener"},{"key":"654_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad014","author":"M Mistretta","year":"2023","unstructured":"Mistretta M, Farini A, Torrente Y, Villa C. Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases. Brain. 2023. https:\/\/doi.org\/10.1093\/brain\/awad014.","journal-title":"Brain"},{"issue":"4","key":"654_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/cpt.2544","volume":"111","author":"S Janicki Hsieh","year":"2022","unstructured":"Janicki Hsieh S, Alexopoulou Z, Mehrotra N, Struyk A, Stoch SA. Neurodegenerative diseases: the value of early predictive end points. Clin Pharmacol Ther. 2022;111(4):835\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"654_CR10","doi-asserted-by":"publisher","first-page":"11454","DOI":"10.1021\/acs.jmedchem.2c00844","volume":"65","author":"Y Fang","year":"2022","unstructured":"Fang Y, Wang J, Zhao M, Zheng Q, Ren C, Wang Y, et al. Progress and challenges in targeted protein degradation for neurodegenerative disease therapy. J Med Chem. 2022;65(17):11454\u201377.","journal-title":"J Med Chem"},{"issue":"1","key":"654_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10367","volume":"8","author":"P Chopade","year":"2023","unstructured":"Chopade P, Chopade N, Zhao Z, Mitragotri S, Liao R, Chandran SV. Alzheimer\u2019s and Parkinson\u2019s disease therapies in the clinic. Bioeng Transl Med. 2023;8(1): e10367.","journal-title":"Bioeng Transl Med"},{"issue":"5","key":"654_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.tins.2020.12.002","volume":"44","author":"M Segarra","year":"2021","unstructured":"Segarra M, Aburto MR, Acker-Palmer A. Blood-brain barrier dynamics to maintain brain homeostasis. Trends Neurosci. 2021;44(5):393\u2013405.","journal-title":"Trends Neurosci"},{"issue":"5","key":"654_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood\u2013brain barrier. Nat Rev Drug Discovery. 2021;20(5):362\u201383.","journal-title":"Nat Rev Drug Discovery"},{"issue":"43","key":"654_CR14","doi-asserted-by":"publisher","first-page":"1701921","DOI":"10.1002\/smll.201701921","volume":"13","author":"YH Tsou","year":"2017","unstructured":"Tsou YH, Zhang XQ, Zhu H, Syed S, Xu X. Drug delivery to the brain across the blood-brain barrier using nanomaterials. Small. 2017;13(43):1701921.","journal-title":"Small"},{"issue":"15","key":"654_CR15","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1039\/D0BM00809E","volume":"8","author":"S Masoudi Asil","year":"2020","unstructured":"Masoudi Asil S, Ahlawat J, Guillama Barroso G, Narayan M. Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases. Biomater Sci. 2020;8(15):4109\u201328.","journal-title":"Biomater Sci"},{"key":"654_CR16","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.biopha.2018.12.133","volume":"111","author":"M Saeedi","year":"2019","unstructured":"Saeedi M, Eslamifar M, Khezri K, Dizaj SM. Applications of nanotechnology in drug delivery to the central nervous system. Biomed Pharmacother. 2019;111:666\u201375.","journal-title":"Biomed Pharmacother"},{"key":"654_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/978-3-030-55035-6_13","volume":"1286","author":"TT Nguyen","year":"2021","unstructured":"Nguyen TT, Vo TK, Vo GV. Therapeutic strategies and nano-drug delivery applications in management of aging Alzheimer\u2019s disease. Adv Exp Med Biol. 2021;1286:183\u201398.","journal-title":"Adv Exp Med Biol"},{"key":"654_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-021-03488-7","author":"TT Nguyen","year":"2021","unstructured":"Nguyen TT, Nguyen TTD, Tran NM, Van Vo G. Lipid-based nanocarriers via nose-to-brain pathway for central nervous system disorders. Neurochem Res. 2021. https:\/\/doi.org\/10.1007\/s11064-021-03488-7.","journal-title":"Neurochem Res"},{"key":"654_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112117","volume":"143","author":"TT Nguyen","year":"2021","unstructured":"Nguyen TT, Dung Nguyen TT, Vo TK, Tran NM, Nguyen MK, Van Vo T, et al. Nanotechnology-based drug delivery for central nervous system disorders. Biomed Pharmacother. 2021;143: 112117.","journal-title":"Biomed Pharmacother"},{"issue":"5601","key":"654_CR20","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1126\/science.1080007","volume":"298","author":"CJ Murphy","year":"2002","unstructured":"Murphy CJ. Materials science. Nanocubes and nanoboxes. Science. 2002;298(5601):2139\u201341.","journal-title":"Science"},{"issue":"5","key":"654_CR21","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1021\/acs.jcim.8b00725","volume":"59","author":"S Zhou","year":"2019","unstructured":"Zhou S, Zhu Y, Yao X, Liu H. Carbon nanoparticles inhibit the aggregation of prion protein as revealed by experiments and atomistic simulations. J Chem Inf Model. 2019;59(5):1909\u201318.","journal-title":"J Chem Inf Model"},{"issue":"2","key":"654_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JAD-2008-13210","volume":"13","author":"A Nazem","year":"2008","unstructured":"Nazem A, Mansoori GA. Nanotechnology solutions for Alzheimer\u2019s disease: advances in research tools, diagnostic methods and therapeutic agents. J Alzheimers Dis. 2008;13(2):199\u2013223.","journal-title":"J Alzheimers Dis"},{"key":"654_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111623","volume":"139","author":"TT Nguyen","year":"2021","unstructured":"Nguyen TT, Nguyen TTD, Nguyen TKO, Vo TK, Vo VG. Advances in developing therapeutic strategies for Alzheimer\u2019s disease. Biomed Pharmacother. 2021;139: 111623.","journal-title":"Biomed Pharmacother"},{"key":"654_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2013.08.008","volume":"71","author":"J Kreuter","year":"2014","unstructured":"Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev. 2014;71:2\u201314.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"654_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/wnan.1157","volume":"4","author":"Z Amoozgar","year":"2012","unstructured":"Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Nanomed Nanobiotechnol. 2012;4(2):219\u201333.","journal-title":"Nanomed Nanobiotechnol"},{"issue":"1","key":"654_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12891-018-1990-1","volume":"19","author":"WR Smith","year":"2018","unstructured":"Smith WR, Hudson PW, Ponce BA, Rajaram Manoharan SR. Nanotechnology in orthopedics: a clinically oriented review. BMC Musculoskelet Disord. 2018;19(1):67.","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"654_CR27","doi-asserted-by":"publisher","first-page":"687","DOI":"10.4155\/tde.13.38","volume":"4","author":"SY Tzeng","year":"2013","unstructured":"Tzeng SY, Green JJ. Therapeutic nanomedicine for brain cancer. Ther Deliv. 2013;4(6):687\u2013704.","journal-title":"Ther Deliv"},{"issue":"3","key":"654_CR28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.nano.2014.12.014","volume":"11","author":"HE Gendelman","year":"2015","unstructured":"Gendelman HE, Anantharam V, Bronich T, Ghaisas S, Jin H, Kanthasamy AG, et al. Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine. 2015;11(3):751\u201367.","journal-title":"Nanomedicine"},{"issue":"8","key":"654_CR29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2174\/1389200217666160728152939","volume":"17","author":"C Kang","year":"2016","unstructured":"Kang C, Sun Y, Zhu J, Li W, Zhang A, Kuang T, et al. Delivery of nanoparticles for treatment of brain tumor. Curr Drug Metab. 2016;17(8):745\u201354.","journal-title":"Curr Drug Metab"},{"issue":"12","key":"654_CR30","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nm.3407","volume":"19","author":"B Obermeier","year":"2013","unstructured":"Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013;19(12):1584\u201396.","journal-title":"Nat Med"},{"key":"654_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108119","volume":"234","author":"G Nehra","year":"2022","unstructured":"Nehra G, Bauer B, Hartz AMS. Blood-brain barrier leakage in Alzheimer\u2019s disease: from discovery to clinical relevance. Pharmacol Ther. 2022;234: 108119.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"654_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ar.b.20087","volume":"289","author":"D Ribatti","year":"2006","unstructured":"Ribatti D, Nico B, Crivellato E, Artico M. Development of the blood-brain barrier: a historical point of view. Anat Rec B New Anat. 2006;289(1):3\u20138.","journal-title":"Anat Rec B New Anat"},{"issue":"13","key":"654_CR33","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.4155\/fmc.12.123","volume":"4","author":"GD Cuny","year":"2012","unstructured":"Cuny GD. Neurodegenerative diseases: challenges and opportunities. Future Med Chem. 2012;4(13):1647\u20139.","journal-title":"Future Med Chem"},{"key":"654_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.mattod.2020.02.001","volume":"37","author":"S Ding","year":"2020","unstructured":"Ding S, Khan AI, Cai X, Song Y, Lyu Z, Du D, et al. Overcoming blood-brain barrier transport: advances in nanoparticle-based drug delivery strategies. Mater Today. 2020;37:112\u201325.","journal-title":"Mater Today"},{"issue":"2","key":"654_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bioactmat.2020.08.017","volume":"6","author":"Y Han","year":"2021","unstructured":"Han Y, Gao C, Wang H, Sun J, Liang M, Feng Y, et al. Macrophage membrane-coated nanocarriers co-modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer\u2019s disease mice. Bioactive Mater. 2021;6(2):529\u201342.","journal-title":"Bioactive Mater"},{"issue":"11","key":"654_CR36","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1039\/C8CS00805A","volume":"48","author":"W Tang","year":"2019","unstructured":"Tang W, Fan W, Lau J, Deng L, Shen Z, Chen X. Emerging blood-brain-barrier-crossing nanotechnology for brain cancer theranostics. Chem Soc Rev. 2019;48(11):2967\u20133014.","journal-title":"Chem Soc Rev"},{"issue":"2","key":"654_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0169-409X(97)00072-0","volume":"28","author":"M Hayashi","year":"1997","unstructured":"Hayashi M, Tomita M, Awazu S. Transcellular and paracellular contribution to transport processes in the colorectal route. Adv Drug Deliv Rev. 1997;28(2):191\u2013204.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5715","key":"654_CR38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/279679a0","volume":"279","author":"JL Goldstein","year":"1979","unstructured":"Goldstein JL, Anderson RGW, Brown MS. Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature. 1979;279(5715):679\u201385.","journal-title":"Nature"},{"issue":"10","key":"654_CR39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.tibtech.2017.06.002","volume":"35","author":"MJ Hajipour","year":"2017","unstructured":"Hajipour MJ, Santoso MR, Rezaee F, Aghaverdi H, Mahmoudi M, Perry G. Advances in Alzheimer\u2019s diagnosis and therapy: the implications of nanotechnology. Trends Biotechnol. 2017;35(10):937\u201353.","journal-title":"Trends Biotechnol"},{"issue":"3","key":"654_CR40","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1021\/cr200472g","volume":"113","author":"S Krol","year":"2013","unstructured":"Krol S, Macrez R, Docagne F, Defer G, Laurent S, Rahman M, et al. Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. Chem Rev. 2013;113(3):1877\u2013903.","journal-title":"Chem Rev"},{"issue":"46","key":"654_CR41","doi-asserted-by":"publisher","first-page":"1801362","DOI":"10.1002\/adma.201801362","volume":"30","author":"D Furtado","year":"2018","unstructured":"Furtado D, Bj\u00f6rnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood\u2013brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater. 2018;30(46):1801362.","journal-title":"Adv Mater"},{"key":"654_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8010013","author":"S Shakeri","year":"2020","unstructured":"Shakeri S, Ashrafizadeh M, Zarrabi A, Roghanian R, Afshar EG, Pardakhty A, et al. Multifunctional polymeric nanoplatforms for brain diseases diagnosis, therapy and theranostics. Biomedicines. 2020. https:\/\/doi.org\/10.3390\/biomedicines8010013.","journal-title":"Biomedicines."},{"issue":"1","key":"654_CR43","doi-asserted-by":"publisher","DOI":"10.1088\/1468-6996\/11\/1\/014101","volume":"11","author":"ZC Xing","year":"2010","unstructured":"Xing ZC, Chang Y, Kang IK. Immobilization of biomolecules on the surface of inorganic nanoparticles for biomedical applications. Sci Technol Adv Mater. 2010;11(1): 014101.","journal-title":"Sci Technol Adv Mater"},{"issue":"1","key":"654_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/1871527321666220222092655","volume":"22","author":"B Hasannejad-Asl","year":"2023","unstructured":"Hasannejad-Asl B, Pooresmaeil F, Choupani E, Dabiri M, Behmardi A, Fadaie M, et al. Nanoparticles as powerful tools for crossing the blood-brain barrier. CNS Neurol Disord. 2023;22(1):18\u201326.","journal-title":"CNS Neurol Disord"},{"issue":"40","key":"654_CR45","doi-asserted-by":"publisher","first-page":"6933","DOI":"10.1002\/adma.201305619","volume":"26","author":"J Deng","year":"2014","unstructured":"Deng J, Yu P, Wang Y, Yang L, Mao L. Visualization and quantification of neurochemicals with gold nanoparticles: opportunities and challenges. Adv Mater. 2014;26(40):6933\u201343.","journal-title":"Adv Mater"},{"key":"654_CR46","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3389\/fneur.2018.00328","volume":"9","author":"A Meola","year":"2018","unstructured":"Meola A, Rao J, Chaudhary N, Sharma M, Chang SD. Gold nanoparticles for brain tumor imaging: a systematic review. Front Neurol. 2018;9:328.","journal-title":"Front Neurol"},{"issue":"1","key":"654_CR47","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1038\/s41467-020-18525-2","volume":"11","author":"K Hou","year":"2020","unstructured":"Hou K, Zhao J, Wang H, Li B, Li K, Shi X, et al. Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer\u2019s disease. Nat Commun. 2020;11(1):4790.","journal-title":"Nat Commun"},{"key":"654_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.111584","volume":"200","author":"J Zhang","year":"2021","unstructured":"Zhang J, Liu R, Zhang D, Zhang Z, Zhu J, Xu L, et al. Neuroprotective effects of maize tetrapeptide-anchored gold nanoparticles in Alzheimer\u2019s disease. Colloids Surf, B. 2021;200: 111584.","journal-title":"Colloids Surf, B"},{"key":"654_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2020.111302","volume":"196","author":"CE da Silva","year":"2020","unstructured":"da Silva CE, de Bem SG, Scussel R, Correa M, da Silva AJ, Luiz GP, et al. Effects of gold nanoparticles administration through behavioral and oxidative parameters in animal model of Parkinson\u2019s disease. Colloids Surf B. 2020;196: 111302.","journal-title":"Colloids Surf B"},{"key":"654_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.mad.2018.02.004","volume":"171","author":"M Zuberek","year":"2018","unstructured":"Zuberek M, St\u0119pkowski TM, Kruszewski M, Grzelak A. Exposure of human neurons to silver nanoparticles induces similar pattern of ABC transporters gene expression as differentiation: study on proliferating and post-mitotic LUHMES cells. Mech Ageing Dev. 2018;171:7\u201314.","journal-title":"Mech Ageing Dev"},{"key":"654_CR51","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.envres.2014.11.006","volume":"136","author":"CL Huang","year":"2015","unstructured":"Huang CL, Hsiao IL, Lin HC, Wang CF, Huang YJ, Chuang CY. Silver nanoparticles affect on gene expression of inflammatory and neurodegenerative responses in mouse brain neural cells. Environ Res. 2015;136:253\u201363.","journal-title":"Environ Res"},{"issue":"20","key":"654_CR52","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.3390\/polym13203547","volume":"13","author":"JV Lim","year":"2021","unstructured":"Lim JV, Bee ST, Tin Sin L, Ratnam CT, Abdul Hamid ZA. A Review on the synthesis, properties, and utilities of functionalized carbon nanoparticles for polymer nanocomposites. Polymers. 2021;13(20):3547.","journal-title":"Polymers"},{"key":"654_CR53","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fnins.2016.00250","volume":"10","author":"M Baldrighi","year":"2016","unstructured":"Baldrighi M, Trusel M, Tonini R, Giordani S. Carbon nanomaterials interfacing with neurons: an in vivo perspective. Front Neurosci. 2016;10:250.","journal-title":"Front Neurosci"},{"key":"654_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105328","volume":"153","author":"C Paviolo","year":"2021","unstructured":"Paviolo C, Cognet L. Near-infrared nanoscopy with carbon-based nanoparticles for the exploration of the brain extracellular space. Neurobiol Dis. 2021;153: 105328.","journal-title":"Neurobiol Dis"},{"issue":"48","key":"654_CR55","doi-asserted-by":"publisher","first-page":"17761","DOI":"10.1021\/jp070712c","volume":"111","author":"S-T Yang","year":"2007","unstructured":"Yang S-T, Guo W, Lin Y, Deng X-Y, Wang H-F, Sun H-F, et al. Biodistribution of pristine single-walled carbon nanotubes in vivo. J Phys Chem C. 2007;111(48):17761\u20134.","journal-title":"J Phys Chem C"},{"issue":"10","key":"654_CR56","doi-asserted-by":"publisher","first-page":"E1968","DOI":"10.1073\/pnas.1616070114","volume":"114","author":"MJ Aragon","year":"2017","unstructured":"Aragon MJ, Topper L, Tyler CR, Sanchez B, Zychowski K, Young T, et al. Serum-borne bioactivity caused by pulmonary multiwalled carbon nanotubes induces neuroinflammation via blood-brain barrier impairment. Proc Natl Acad Sci USA. 2017;114(10):E1968\u201376.","journal-title":"Proc Natl Acad Sci USA"},{"key":"654_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cis.2020.102123","volume":"278","author":"M Ashrafizadeh","year":"2020","unstructured":"Ashrafizadeh M, Mohammadinejad R, Kailasa SK, Ahmadi Z, Afshar EG, Pardakhty A. Carbon dots as versatile nanoarchitectures for the treatment of neurological disorders and their theranostic applications: a review. Adv Coll Interface Sci. 2020;278: 102123.","journal-title":"Adv Coll Interface Sci"},{"key":"654_CR58","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.colsurfb.2019.01.031","volume":"176","author":"KJ Mintz","year":"2019","unstructured":"Mintz KJ, Mercado G, Zhou Y, Ji Y, Hettiarachchi SD, Liyanage PY, et al. Tryptophan carbon dots and their ability to cross the blood-brain barrier. Colloids Surf B. 2019;176:488\u201393.","journal-title":"Colloids Surf B"},{"issue":"1","key":"654_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1567201818666210910162750","volume":"19","author":"SNA Bukhari","year":"2022","unstructured":"Bukhari SNA. Nanotherapeutics for Alzheimer\u2019s disease with preclinical evaluation and clinical trials: challenges, promises and limitations. Curr Drug Deliv. 2022;19(1):17\u201331.","journal-title":"Curr Drug Deliv"},{"issue":"12","key":"654_CR60","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/jcm7120490","volume":"7","author":"DM Teleanu","year":"2018","unstructured":"Teleanu DM, Chircov C, Grumezescu AM, Volceanov A, Teleanu RI. Impact of nanoparticles on brain health: an up to date overview. J Clin Med. 2018;7(12):490.","journal-title":"J Clin Med"},{"issue":"10","key":"654_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048515","volume":"7","author":"EA Tanifum","year":"2012","unstructured":"Tanifum EA, Dasgupta I, Srivastava M, Bhavane RC, Sun L, Berridge J, et al. Intravenous delivery of targeted liposomes to amyloid-\u03b2 pathology in APP\/PSEN1 transgenic mice. PLoS\u00a0One. 2012;7(10): e48515.","journal-title":"PLoS\u00a0One"},{"issue":"12","key":"654_CR62","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.1007\/s11095-015-1744-9","volume":"32","author":"X Zheng","year":"2015","unstructured":"Zheng X, Shao X, Zhang C, Tan Y, Liu Q, Wan X, et al. Intranasal H102 Peptide-loaded liposomes for brain delivery to treat Alzheimer\u2019s disease. Pharm Res. 2015;32(12):3837\u201349.","journal-title":"Pharm Res"},{"key":"654_CR63","doi-asserted-by":"publisher","first-page":"951","DOI":"10.2147\/IJN.S30721","volume":"8","author":"P Ramos-Cabrer","year":"2013","unstructured":"Ramos-Cabrer P, Campos F. Liposomes and nanotechnology in drug development: focus on neurological targets. Int J Nanomed. 2013;8:951\u201360.","journal-title":"Int J Nanomed"},{"issue":"25","key":"654_CR64","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1016\/j.biomaterials.2010.04.044","volume":"31","author":"M Gobbi","year":"2010","unstructured":"Gobbi M, Re F, Canovi M, Beeg M, Gregori M, Sesana S, et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials. 2010;31(25):6519\u201329.","journal-title":"Biomaterials"},{"issue":"2","key":"654_CR65","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.nano.2014.09.015","volume":"11","author":"L Ord\u00f3\u00f1ez-Guti\u00e9rrez","year":"2015","unstructured":"Ord\u00f3\u00f1ez-Guti\u00e9rrez L, Re F, Bereczki E, Ioja E, Gregori M, Andersen AJ, et al. Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-\u03b2 levels in APP\/PS1 transgenic mice. Nanomedicine. 2015;11(2):421\u201330.","journal-title":"Nanomedicine"},{"key":"654_CR66","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neulet.2015.03.016","volume":"593","author":"F Sa","year":"2015","unstructured":"Sa F, Zhang LQ, Chong CM, Guo BJ, Li S, Zhang ZJ, et al. Discovery of novel anti-parkinsonian effect of schisantherin A in in vitro and in vivo. Neurosci Lett. 2015;593:7\u201312.","journal-title":"Neurosci Lett"},{"key":"654_CR67","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jep.2015.04.040","volume":"170","author":"LQ Zhang","year":"2015","unstructured":"Zhang LQ, Sa F, Chong CM, Wang Y, Zhou ZY, Chang RC, et al. Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS\/NO and AKT\/GSK3\u03b2 pathways. J Ethnopharmacol. 2015;170:8\u201315.","journal-title":"J Ethnopharmacol"},{"issue":"11","key":"654_CR68","doi-asserted-by":"publisher","first-page":"9516","DOI":"10.1021\/acsami.7b01171","volume":"9","author":"T Chen","year":"2017","unstructured":"Chen T, Li C, Li Y, Yi X, Wang R, Lee SM, et al. Small-sized mPEG-PLGA nanoparticles of Schisantherin A with sustained release for enhanced brain uptake and anti-Parkinsonian activity. ACS Appl Mater Interfaces. 2017;9(11):9516\u201327.","journal-title":"ACS Appl Mater Interfaces."},{"issue":"11","key":"654_CR69","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2019.1676720","volume":"16","author":"K Kardani","year":"2019","unstructured":"Kardani K, Milani A, Shabani HS, Bolhassani A. Cell penetrating peptides: the potent multi-cargo intracellular carriers. Expert Opin Drug Deliver. 2019;16(11):1227\u201358.","journal-title":"Expert Opin Drug Deliver"},{"issue":"4","key":"654_CR70","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","volume":"38","author":"G Guidotti","year":"2017","unstructured":"Guidotti G, Brambilla L, Rossi D. Cell-penetrating peptides: from basic research to clinics. Trends Pharmacol Sci. 2017;38(4):406\u201324.","journal-title":"Trends Pharmacol Sci"},{"issue":"1\u20132","key":"654_CR71","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ijpharm.2016.01.068","volume":"501","author":"J Li","year":"2016","unstructured":"Li J, Zhang X, Wang M, Li X, Mu H, Wang A, et al. Synthesis of a bi-functional dendrimer-based nanovehicle co-modified with RGDyC and TAT peptides for neovascular targeting and penetration. Int J Pharm. 2016;501(1\u20132):112\u201323.","journal-title":"Int J Pharm"},{"issue":"6","key":"654_CR72","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/ijms17060806","volume":"17","author":"G Sharma","year":"2016","unstructured":"Sharma G, Lakkadwala S, Modgil A, Singh J. The role of cell-penetrating peptide and transferrin on enhanced delivery of drug to brain. Int J Mol Sci. 2016;17(6):806.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"654_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2013.01.016","volume":"167","author":"G Sharma","year":"2013","unstructured":"Sharma G, Modgil A, Layek B, Arora K, Sun C, Law B, et al. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J Control Release. 2013;167(1):1\u201310.","journal-title":"J Control Release"},{"issue":"14","key":"654_CR74","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1016\/j.jmb.2020.04.002","volume":"432","author":"ZR Crook","year":"2020","unstructured":"Crook ZR, Girard E, Sevilla GP, Merrill M, Friend D, Rupert PB, et al. A TfR-binding cystine-dense peptide promotes blood-brain barrier penetration of bioactive molecules. J Mol Biol. 2020;432(14):3989\u20134009.","journal-title":"J Mol Biol"},{"issue":"11","key":"654_CR75","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acschemneuro.0c00076","volume":"11","author":"S Arora","year":"2020","unstructured":"Arora S, Sharma D, Singh J. GLUT-1: An effective target to deliver brain-derived neurotrophic factor gene across the blood brain barrier. ACS Chem Neurosci. 2020;11(11):1620\u201333.","journal-title":"ACS Chem Neurosci"},{"issue":"2","key":"654_CR76","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10571-013-9999-3","volume":"34","author":"BP Meloni","year":"2014","unstructured":"Meloni BP, Craig AJ, Milech N, Hopkins RM, Watt PM, Knuckey NW. The neuroprotective efficacy of cell-penetrating peptides TAT, penetratin, Arg-9, and Pep-1 in glutamic acid, kainic acid, and in vitro ischemia injury models using primary cortical neuronal cultures. Cell Mol Neurobiol. 2014;34(2):173\u201381.","journal-title":"Cell Mol Neurobiol"},{"issue":"9","key":"654_CR77","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.bbamem.2007.06.003","volume":"1768","author":"AK Cardozo","year":"2007","unstructured":"Cardozo AK, Buchillier V, Mathieu M, Chen J, Ortis F, Ladri\u00e8re L, et al. Cell-permeable peptides induce dose- and length-dependent cytotoxic effects. Biochem Biophys Acta. 2007;1768(9):2222\u201334.","journal-title":"Biochem Biophys Acta"},{"issue":"1","key":"654_CR78","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1056\/NEJMra040223","volume":"351","author":"JL Cummings","year":"2004","unstructured":"Cummings JL. Alzheimer\u2019s disease. N Engl J Med. 2004;351(1):56\u201367.","journal-title":"N Engl J Med"},{"issue":"17","key":"654_CR79","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1002\/anie.200802808","volume":"48","author":"R Jakob-Roetne","year":"2009","unstructured":"Jakob-Roetne R, Jacobsen H. Alzheimer\u2019s disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl. 2009;48(17):3030\u201359.","journal-title":"Angew Chem Int Ed Engl"},{"key":"654_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-020-03031-0","author":"TT Nguyen","year":"2020","unstructured":"Nguyen TT, Ta QTH, Nguyen TTD, Le TT, Vo VG. Role of insulin resistance in the Alzheimer\u2019s disease progression. Neurochem Res. 2020. https:\/\/doi.org\/10.1007\/s11064-020-03031-0.","journal-title":"Neurochem Res"},{"issue":"9","key":"654_CR81","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.3390\/ijms21093165","volume":"21","author":"TT Nguyen","year":"2020","unstructured":"Nguyen TT, Ta QTH, Nguyen TKO, Nguyen TTD, Giau VV. Type 3 diabetes and its role implications in Alzheimer\u2019s disease. Int J Mol Sci. 2020;21(9):3165.","journal-title":"Int J Mol Sci"},{"key":"654_CR82","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jns.2017.03.031","volume":"376","author":"E Bagyinszky","year":"2017","unstructured":"Bagyinszky E, Giau VV, Shim K, Suk K, An SSA, Kim S. Role of inflammatory molecules in the Alzheimer\u2019s disease progression and diagnosis. J Neurol Sci. 2017;376:242\u201354.","journal-title":"J Neurol Sci"},{"key":"654_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117996","volume":"256","author":"AADT Abeysinghe","year":"2020","unstructured":"Abeysinghe AADT, Deshapriya RDUS, Udawatte C. Alzheimer\u2019s disease; a review of the pathophysiological basis and therapeutic interventions. Life Sci. 2020;256: 117996.","journal-title":"Life Sci"},{"issue":"3","key":"654_CR84","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","volume":"16","author":"R Briggs","year":"2016","unstructured":"Briggs R, Kennelly SP, O\u2019Neill D. Drug treatments in Alzheimer\u2019s disease. Clin Med. 2016;16(3):247\u201353.","journal-title":"Clin Med"},{"key":"654_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6217","volume":"367","author":"E Joe","year":"2019","unstructured":"Joe E, Ringman JM. Cognitive symptoms of Alzheimer\u2019s disease: clinical management and prevention. BMJ. 2019;367: l6217.","journal-title":"BMJ"},{"issue":"3","key":"654_CR86","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20(3):148\u201360.","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"654_CR87","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41583-020-0325-z","volume":"21","author":"S Saez-Atienzar","year":"2020","unstructured":"Saez-Atienzar S, Masliah E. Cellular senescence and Alzheimer disease: the egg and the chicken scenario. Nat Rev Neurosci. 2020;21(8):433\u201344.","journal-title":"Nat Rev Neurosci"},{"issue":"25","key":"654_CR88","doi-asserted-by":"publisher","first-page":"21116","DOI":"10.1021\/acsami.7b03816","volume":"9","author":"Q Han","year":"2017","unstructured":"Han Q, Cai S, Yang L, Wang X, Qi C, Yang R, et al. Molybdenum disulfide nanoparticles as multifunctional inhibitors against Alzheimer\u2019s disease. ACS Appl Mater Interfaces. 2017;9(25):21116\u201323.","journal-title":"ACS Appl Mater Interfaces"},{"key":"654_CR89","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.msec.2017.04.027","volume":"77","author":"AP Muller","year":"2017","unstructured":"Muller AP, Ferreira GK, da Silva S, Nesi RT, de Bem SG, Mendes C, et al. Safety protocol for the gold nanoparticles administration in rats. Mater Sci Eng C Mater Biol Appl. 2017;77:1145\u201350.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"7","key":"654_CR90","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.nano.2017.06.013","volume":"13","author":"F Morales-Zavala","year":"2017","unstructured":"Morales-Zavala F, Arriagada H, Hassan N, Velasco C, Riveros A, \u00c1lvarez AR, et al. Peptide multifunctionalized gold nanorods decrease toxicity of \u03b2-amyloid peptide in a Caenorhabditis elegans model of Alzheimer\u2019s disease. Nanomedicine. 2017;13(7):2341\u201350.","journal-title":"Nanomedicine"},{"issue":"19","key":"654_CR91","doi-asserted-by":"publisher","first-page":"1807965","DOI":"10.1002\/adma.201807965","volume":"31","author":"D Kim","year":"2019","unstructured":"Kim D, Kwon HJ, Hyeon T. Magnetite\/ceria nanoparticle assemblies for extracorporeal cleansing of amyloid-\u03b2 in Alzheimer\u2019s disease. Adv Mater. 2019;31(19):1807965.","journal-title":"Adv Mater"},{"issue":"8","key":"654_CR92","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/nbt994","volume":"22","author":"X Gao","year":"2004","unstructured":"Gao X, Cui Y, Levenson RM, Chung LWK, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004;22(8):969\u201376.","journal-title":"Nat Biotechnol"},{"issue":"26","key":"654_CR93","doi-asserted-by":"publisher","first-page":"30261","DOI":"10.1021\/acsami.1c00690","volume":"13","author":"X Guo","year":"2021","unstructured":"Guo X, Lie Q, Liu Y, Jia Z, Gong Y, Yuan X, et al. Multifunctional selenium quantum dots for the treatment of Alzheimer\u2019s disease by reducing A\u03b2-Neurotoxicity and oxidative stress and alleviate neuroinflammation. ACS Appl Mater Interfaces. 2021;13(26):30261\u201373.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"11","key":"654_CR94","doi-asserted-by":"publisher","first-page":"13079","DOI":"10.1021\/acsami.2c01090","volume":"14","author":"M Sharma","year":"2022","unstructured":"Sharma M, Tiwari V, Chaturvedi S, Wahajuddin M, Shukla S, Panda JJ. Self-fluorescent lone tryptophan nanoparticles as theranostic agents against Alzheimer\u2019s disease. ACS Appl Mater Interfaces. 2022;14(11):13079\u201393.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"654_CR95","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(21)00330-6","volume":"21","author":"D Weintraub","year":"2022","unstructured":"Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, et al. The neuropsychiatry of Parkinson\u2019s disease: advances and challenges. Lancet Neurol. 2022;21(1):89\u2013102.","journal-title":"Lancet Neurol"},{"issue":"11","key":"654_CR96","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/nrd.2018.136","volume":"17","author":"D Charvin","year":"2018","unstructured":"Charvin D, Medori R, Hauser RA, Rascol O. Therapeutic strategies for Parkinson disease: Beyond dopaminergic drugs. Nat Rev Drug Discovery. 2018;17(11):804\u201322.","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"654_CR97","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","volume":"15","author":"A Elkouzi","year":"2019","unstructured":"Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS. Emerging therapies in Parkinson disease\u2014repurposed drugs and new approaches. Nat Rev Neurol. 2019;15(4):204\u201323.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"654_CR98","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s11064-022-03617-w","volume":"47","author":"TT Nguyen","year":"2022","unstructured":"Nguyen TT, Bao NS, Van Vo G. Advances in hydrogel-based drug delivery systems for Parkinson\u2019s disease. Neurochem Res. 2022;47(8):2129\u201341.","journal-title":"Neurochem Res"},{"key":"654_CR99","doi-asserted-by":"publisher","first-page":"6989","DOI":"10.2147\/IJN.S220380","volume":"14","author":"Z Zand","year":"2019","unstructured":"Zand Z, Khaki PA, Salihi A, Sharifi M, Qadir Nanakali NM, Alasady AA, et al. Cerium oxide NPs mitigate the amyloid formation of \u03b1-synuclein and associated cytotoxicity. Int J Nanomed. 2019;14:6989\u20137000.","journal-title":"Int J Nanomed"},{"issue":"2","key":"654_CR100","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/nano10020235","volume":"10","author":"R Ruotolo","year":"2020","unstructured":"Ruotolo R, De Giorgio G, Minato I, Bianchi MG, Bussolati O, Marmiroli N. Cerium oxide nanoparticles rescue \u03b1-synuclein-induced toxicity in a yeast model of Parkinson\u2019s disease. Nanomaterials. 2020;10(2):235.","journal-title":"Nanomaterials"},{"issue":"23","key":"654_CR101","doi-asserted-by":"publisher","first-page":"2101316","DOI":"10.1002\/adhm.202101316","volume":"10","author":"Z Xu","year":"2021","unstructured":"Xu Z, Qu A, Wang W, Lu M, Shi B, Chen C, et al. Facet-dependent biodegradable Mn3O4 nanoparticles for ameliorating Parkinson\u2019s disease. Adv Healthcare Mater. 2021;10(23):2101316.","journal-title":"Adv Healthcare Mater"},{"issue":"5","key":"654_CR102","doi-asserted-by":"publisher","first-page":"8592","DOI":"10.1021\/acsnano.1c00453","volume":"15","author":"J Garc\u00eda-Pardo","year":"2021","unstructured":"Garc\u00eda-Pardo J, Novio F, Nador F, Cavaliere I, Su\u00e1rez-Garc\u00eda S, Lope-Piedrafita S, et al. Bioinspired theranostic coordination polymer nanoparticles for intranasal dopamine replacement in Parkinson\u2019s disease. ACS Nano. 2021;15(5):8592\u2013609.","journal-title":"ACS Nano"},{"issue":"3","key":"654_CR103","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1021\/acs.bioconjchem.8b00894","volume":"30","author":"I Rusiecka","year":"2019","unstructured":"Rusiecka I, Ruczy\u0144ski J, Koz\u0142owska A, Backtrog E, Mucha P, Koci\u0107 I, et al. TP10-dopamine conjugate as a potential therapeutic agent in the treatment of Parkinson\u2019s disease. Bioconjug Chem. 2019;30(3):760\u201374.","journal-title":"Bioconjug Chem"},{"issue":"48","key":"654_CR104","doi-asserted-by":"publisher","first-page":"45276","DOI":"10.1021\/acsami.9b16047","volume":"11","author":"T Chen","year":"2019","unstructured":"Chen T, Liu W, Xiong S, Li D, Fang S, Wu Z, et al. Nanoparticles mediating the sustained puerarin release facilitate improved brain delivery to treat Parkinson\u2019s disease. ACS Appl Mater Interfaces. 2019;11(48):45276\u201389.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"16","key":"654_CR105","doi-asserted-by":"publisher","first-page":"18964","DOI":"10.1021\/acsami.9b21215","volume":"12","author":"J Ahlawat","year":"2020","unstructured":"Ahlawat J, Neupane R, Deemer E, Sreenivasan ST, Narayan M. Chitosan\u2013ellagic acid nanohybrid for mitigating rotenone-induced oxidative stress. ACS Appl Mater Interfaces. 2020;12(16):18964\u201377.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"654_CR106","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3390\/molecules26030543","volume":"26","author":"M Pichla","year":"2021","unstructured":"Pichla M, Bartosz G, Stefaniuk I, Sadowska-Bartosz I. pH-responsive redox nanoparticles protect SH-SY5Y cells at lowered pH in a cellular model of Parkinson\u2019s disease. Molecules. 2021;26(3):543.","journal-title":"Molecules"},{"issue":"10107","key":"654_CR107","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","volume":"390","author":"MA van Es","year":"2017","unstructured":"van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084\u201398.","journal-title":"Lancet"},{"issue":"5","key":"654_CR108","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1474-4422(21)00414-2","volume":"21","author":"SA Goutman","year":"2022","unstructured":"Goutman SA, Hardiman O, Al-Chalabi A, Chi\u00f3 A, Savelieff MG, Kiernan MC, et al. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol. 2022;21(5):465\u201379.","journal-title":"Lancet Neurol"},{"issue":"7628","key":"654_CR109","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature20413","volume":"539","author":"JP Taylor","year":"2016","unstructured":"Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature. 2016;539(7628):197\u2013206.","journal-title":"Nature"},{"issue":"2","key":"654_CR110","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41582-020-00434-z","volume":"17","author":"MC Kiernan","year":"2021","unstructured":"Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104\u201318.","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"654_CR111","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.nano.2016.06.009","volume":"12","author":"W DeCoteau","year":"2016","unstructured":"DeCoteau W, Heckman KL, Estevez AY, Reed KJ, Costanzo W, Sandford D, et al. Cerium oxide nanoparticles with antioxidant properties ameliorate strength and prolong life in mouse model of amyotrophic lateral sclerosis. Nanomedicine. 2016;12(8):2311\u201320.","journal-title":"Nanomedicine"},{"issue":"1","key":"654_CR112","doi-asserted-by":"publisher","first-page":"20675","DOI":"10.1038\/s41598-020-77578-x","volume":"10","author":"MF Leyton-Jaimes","year":"2020","unstructured":"Leyton-Jaimes MF, Ivert P, Hoeber J, Han Y, Feiler A, Zhou C, et al. Empty mesoporous silica particles significantly delay disease progression and extend survival in a mouse model of ALS. Sci Rep. 2020;10(1):20675.","journal-title":"Sci Rep"},{"key":"654_CR113","doi-asserted-by":"crossref","unstructured":"Marcuzzo S, Isaia D, Bonanno S, Malacarne C, Cavalcante P, Zacheo A, et al. FM19G11-loaded gold nanoparticles enhance the proliferation and self-renewal of ependymal stem progenitor cells derived from ALS mice. Cells. 2019;8(3).","DOI":"10.3390\/cells8030279"},{"key":"654_CR114","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fbioe.2020.00224","volume":"8","author":"DX Medina","year":"2020","unstructured":"Medina DX, Chung EP, Teague CD, Bowser R, Sirianni RW. Intravenously administered, retinoid activating nanoparticles increase lifespan and reduce neurodegeneration in the SOD1(G93A) mouse model of ALS. Frontiers in Bioengineering and Biotechnology. 2020;8:224.","journal-title":"Frontiers in Bioengineering and Biotechnology."},{"key":"654_CR115","doi-asserted-by":"crossref","unstructured":"Teixeira MI, Lopes CM, Gon\u00e7alves H, Catita J, Silva AM, Rodrigues F, Amaral MH, Costa PC. Formulation, Characterization, and Cytotoxicity Evaluation of Lactoferrin Functionalized Lipid Nanoparticles for Riluzole Delivery to the Brain. Pharmaceutics. 2022 Jan 13;14(1):185. https:\/\/doi.org\/10.3390\/pharmaceutics14010185.","DOI":"10.3390\/pharmaceutics14010185"},{"issue":"6","key":"654_CR116","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1021\/acs.molpharmaceut.1c00297","volume":"18","author":"GR Ediriweera","year":"2021","unstructured":"Ediriweera GR, Chen L, Yerbury JJ, Thurecht KJ, Vine KL. Non-viral vector-mediated gene therapy for ALS: challenges and future perspectives. Mol Pharm. 2021;18(6):2142\u201360.","journal-title":"Mol Pharm"},{"key":"654_CR117","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/B978-0-444-52014-2.00004-5","volume":"100","author":"JP Vonsattel","year":"2011","unstructured":"Vonsattel JP, Keller C, Cortes Ramirez EP. Huntington\u2019s disease\u2014neuropathology. Handb Clin Neurol. 2011;100:83\u2013100.","journal-title":"Handb Clin Neurol"},{"key":"654_CR118","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","volume":"4","author":"DO Claassen","year":"2017","unstructured":"Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, et al. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J Clin Movement Disord. 2017;4:3.","journal-title":"J Clin Movement Disord."},{"issue":"28","key":"654_CR119","doi-asserted-by":"publisher","first-page":"24126","DOI":"10.1021\/acsami.7b06510","volume":"9","author":"K Debnath","year":"2017","unstructured":"Debnath K, Pradhan N, Singh BK, Jana NR, Jana NR. Poly(trehalose) nanoparticles prevent amyloid aggregation and suppress polyglutamine aggregation in a Huntington\u2019s disease model mouse. ACS Appl Mater Interfaces. 2017;9(28):24126\u201339.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"51","key":"654_CR120","doi-asserted-by":"publisher","first-page":"60894","DOI":"10.1021\/acsami.1c18754","volume":"13","author":"D Wahyuningtyas","year":"2021","unstructured":"Wahyuningtyas D, Chen W-H, He R-Y, Huang Y-A, Tsao C-K, He Y-J, et al. Polyglutamine-specific gold nanoparticle complex alleviates mutant Huntingtin-induced toxicity. ACS Appl Mater Interfaces. 2021;13(51):60894\u2013906.","journal-title":"ACS Appl Mater Interfaces"},{"key":"654_CR121","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/IJN.S61288","volume":"9","author":"C-T Lu","year":"2014","unstructured":"Lu C-T, Zhao Y-Z, Wong HL, Cai J, Peng L, Tian X-Q. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomed. 2014;9:2241\u201357.","journal-title":"Int J Nanomed"},{"issue":"1","key":"654_CR122","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12640-019-00086-y","volume":"37","author":"MS Abdelfattah","year":"2020","unstructured":"Abdelfattah MS, Badr SEA, Lotfy SA, Attia GH, Aref AM, Abdel Moneim AE, et al. Rutin and selenium co-administration reverse 3-nitropropionic acid-induced neurochemical and molecular impairments in a mouse model of Huntington\u2019s disease. Neurotox Res. 2020;37(1):77\u201392.","journal-title":"Neurotox Res"},{"issue":"38","key":"654_CR123","doi-asserted-by":"publisher","first-page":"34725","DOI":"10.1021\/acsami.9b12319","volume":"11","author":"W Cong","year":"2019","unstructured":"Cong W, Bai R, Li YF, Wang L, Chen C. Selenium nanoparticles as an efficient nanomedicine for the therapy of Huntington\u2019s disease. ACS Appl Mater Interfaces. 2019;11(38):34725\u201335.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"38","key":"654_CR124","doi-asserted-by":"publisher","first-page":"34725","DOI":"10.1021\/acsami.9b12319","volume":"11","author":"W Cong","year":"2019","unstructured":"Cong W, Bai R, Li Y-F, Wang L, Chen C. Selenium nanoparticles as an efficient nanomedicine for the therapy of Huntington\u2019s disease. ACS Appl Mater Interfaces. 2019;11(38):34725\u201335.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"18","key":"654_CR125","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1093\/hmg\/ddl210","volume":"15","author":"DE Ehrnhoefer","year":"2006","unstructured":"Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington\u2019s disease models. Hum Mol Genet. 2006;15(18):2743\u201351.","journal-title":"Hum Mol Genet"},{"issue":"31","key":"654_CR126","doi-asserted-by":"publisher","first-page":"20309","DOI":"10.1021\/acsami.6b06853","volume":"8","author":"K Debnath","year":"2016","unstructured":"Debnath K, Shekhar S, Kumar V, Jana NR, Jana NR. Efficient inhibition of protein aggregation, disintegration of aggregates, and lowering of cytotoxicity by green tea polyphenol-based self-assembled polymer nanoparticles. ACS Appl Mater Interfaces. 2016;8(31):20309\u201318.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"12","key":"654_CR127","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.15252\/emmm.201505413","volume":"7","author":"M Valenza","year":"2015","unstructured":"Valenza M, Chen JY, Di Paolo E, Ruozi B, Belletti D, Ferrari Bardile C, et al. Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington\u2019s disease mice. EMBO Mol Med. 2015;7(12):1547\u201364.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"654_CR128","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1021\/mp3003946","volume":"10","author":"BM Godinho","year":"2013","unstructured":"Godinho BM, Ogier JR, Darcy R, O\u2019Driscoll CM, Cryan JF. Self-assembling modified \u03b2-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington\u2019s disease. Mol Pharm. 2013;10(2):640\u20139.","journal-title":"Mol Pharm"},{"key":"654_CR129","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jconrel.2022.01.044","volume":"343","author":"R Taliyan","year":"2022","unstructured":"Taliyan R, Kakoty V, Sarathlal KC, Kharavtekar SS, Karennanavar CR, Choudhary YK, et al. Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer\u2019s disease. J Control Release. 2022;343:528\u201350.","journal-title":"J Control Release"},{"issue":"35","key":"654_CR130","doi-asserted-by":"publisher","first-page":"2003054","DOI":"10.1002\/adfm.202003054","volume":"30","author":"S Mukherjee","year":"2020","unstructured":"Mukherjee S, Madamsetty VS, Bhattacharya D, Roy Chowdhury S, Paul MK, Mukherjee A. Recent advancements of nanomedicine in neurodegenerative disorders theranostics. Adv Func Mater. 2020;30(35):2003054.","journal-title":"Adv Func Mater"},{"issue":"S9","key":"654_CR131","doi-asserted-by":"publisher","DOI":"10.1002\/alz.057586","volume":"17","author":"ME Barton","year":"2021","unstructured":"Barton ME, Byrnes W, Mesa IR, Bloemers J, Maguire RP, Bouw R, et al. Design of a patient- and investigator-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer\u2019s disease: the TOGETHER Study, AH0003. Alzheimers Dement. 2021;17(S9): e057586.","journal-title":"Alzheimers Dement"},{"key":"654_CR132","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.addr.2016.02.008","volume":"103","author":"M Nair","year":"2016","unstructured":"Nair M, Jayant RD, Kaushik A, Sagar V. Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev. 2016;103:202\u201317.","journal-title":"Adv Drug Deliv Rev"},{"key":"654_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2019.107082","volume":"166","author":"T Dara","year":"2019","unstructured":"Dara T, Vatanara A, Sharifzadeh M, Khani S, Vakilinezhad MA, Vakhshiteh F, et al. Improvement of memory deficits in the rat model of Alzheimer\u2019s disease by erythropoietin-loaded solid lipid nanoparticles. Neurobiol Learn Mem. 2019;166: 107082.","journal-title":"Neurobiol Learn Mem"},{"key":"654_CR134","doi-asserted-by":"publisher","DOI":"10.1016\/j.dyepig.2019.107968","volume":"173","author":"J Cai","year":"2020","unstructured":"Cai J, Dao P, Chen H, Yan L, Li YL, Zhang W, et al. Ultrasmall superparamagnetic iron oxide nanoparticles-bound NIR dyes: Novel theranostic agents for Alzheimer\u2019s disease. Dyes Pigm. 2020;173: 107968.","journal-title":"Dyes Pigm"},{"issue":"7","key":"654_CR135","doi-asserted-by":"publisher","first-page":"12833","DOI":"10.1021\/acsomega.9b01411","volume":"4","author":"SK Sonawane","year":"2019","unstructured":"Sonawane SK, Ahmad A, Chinnathambi S. Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer\u2019s disease. ACS Omega. 2019;4(7):12833\u201340.","journal-title":"ACS Omega"},{"issue":"25","key":"654_CR136","doi-asserted-by":"publisher","first-page":"13757","DOI":"10.1039\/D0NR04037A","volume":"12","author":"EA Burilova","year":"2020","unstructured":"Burilova EA, Pashirova TN, Zueva IV, Gibadullina EM, Lushchekina SV, Sapunova AS, et al. Bi-functional sterically hindered phenol lipid-based delivery systems as potential multi-target agents against Alzheimer\u2019s disease via an intranasal route. Nanoscale. 2020;12(25):13757\u201370.","journal-title":"Nanoscale"},{"issue":"39","key":"654_CR137","doi-asserted-by":"publisher","first-page":"44180","DOI":"10.1021\/acsami.0c13223","volume":"12","author":"M Sharma","year":"2020","unstructured":"Sharma M, Tiwari V, Shukla S, Panda JJ. Fluorescent dopamine-tryptophan nanocomposites as dual-imaging and antiaggregation agents: new generation of amyloid theranostics with trimeric effects. ACS Appl Mater Interfaces. 2020;12(39):44180\u201394.","journal-title":"ACS Appl Mater Interfaces"},{"key":"654_CR138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105314","volume":"148","author":"RGR Pinheiro","year":"2020","unstructured":"Pinheiro RGR, Granja A, Loureiro JA, Pereira MC, Pinheiro M, Neves AR, et al. Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer\u2019s disease. Eur J Pharm Sci. 2020;148: 105314.","journal-title":"Eur J Pharm Sci"},{"issue":"7","key":"654_CR139","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11095-020-02865-1","volume":"37","author":"RGR Pinheiro","year":"2020","unstructured":"Pinheiro RGR, Granja A, Loureiro JA, Pereira MC, Pinheiro M, Neves AR, et al. RVG29-functionalized lipid nanoparticles for quercetin brain delivery and Alzheimer\u2019s disease. Pharm Res. 2020;37(7):139.","journal-title":"Pharm Res"},{"issue":"43","key":"654_CR140","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202002804","volume":"16","author":"W Gao","year":"2020","unstructured":"Gao W, Wang W, Dong X, Sun Y. Nitrogen-doped carbonized polymer dots: a potent scavenger and detector targeting Alzheimer\u2019s \u03b2-amyloid plaques. Small. 2020;16(43): e2002804.","journal-title":"Small"},{"issue":"11","key":"654_CR141","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s11095-017-2240-1","volume":"34","author":"N Mittapelly","year":"2017","unstructured":"Mittapelly N, Thalla M, Pandey G, Banala VT, Sharma S, Arya A, et al. Long acting ionically paired embonate based nanocrystals of donepezil for the treatment of Alzheimer\u2019s disease: a proof of concept study. Pharm Res. 2017;34(11):2322\u201335.","journal-title":"Pharm Res"},{"issue":"Pt 1","key":"654_CR142","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijbiomac.2017.07.021","volume":"105","author":"K AnjiReddy","year":"2017","unstructured":"AnjiReddy K, Karpagam S. Chitosan nanofilm and electrospun nanofiber for quick drug release in the treatment of Alzheimer\u2019s disease: in vitro and in vivo evaluation. Int J Biol Macromol. 2017;105(Pt 1):131\u201342.","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"654_CR143","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/03639045.2012.758130","volume":"40","author":"S Md","year":"2014","unstructured":"Md S, Ali M, Baboota S, Sahni JK, Bhatnagar A, Ali J. Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev Ind Pharm. 2014;40(2):278\u201387.","journal-title":"Drug Dev Ind Pharm"},{"issue":"9","key":"654_CR144","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1021\/acschemneuro.9b00343","volume":"10","author":"KV Krishna","year":"2019","unstructured":"Krishna KV, Wadhwa G, Alexander A, Kanojia N, Saha RN, Kukreti R, et al. Design and biological evaluation of lipoprotein-based donepezil nanocarrier for enhanced brain uptake through oral delivery. ACS Chem Neurosci. 2019;10(9):4124\u201335.","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"654_CR145","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1166\/jbn.2014.1719","volume":"10","author":"KP Pagar","year":"2014","unstructured":"Pagar KP, Sardar SM, Vavia PR. Novel L-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer\u2019s disease. J Biomed Nanotechnol. 2014;10(3):415\u201326.","journal-title":"J Biomed Nanotechnol"},{"issue":"1","key":"654_CR146","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejps.2012.04.013","volume":"47","author":"M Fazil","year":"2012","unstructured":"Fazil M, Md S, Haque S, Kumar M, Baboota S, Sahni JK, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci. 2012;47(1):6\u201315.","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"654_CR147","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1021\/acschemneuro.9b00691","volume":"11","author":"H Mohamadpour","year":"2020","unstructured":"Mohamadpour H, Azadi A, Rostamizadeh K, Andalib S, Saghatchi Zanjani MR, Hamidi M. Preparation, optimization, and evaluation of methoxy poly(ethylene glycol)-co-poly(\u03b5-caprolactone) nanoparticles loaded by rivastigmine for brain delivery. ACS Chem Neurosci. 2020;11(5):783\u201395.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"654_CR148","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1567201815666181004094707","volume":"16","author":"Sunena","year":"2019","unstructured":"Sunena, Singh SK, Mishra DN. Nose to Brain Delivery of galantamine loaded nanoparticles: in-vivo pharmacodynamic and biochemical study in mice. Curr Drug Deliver. 2019;16(1):51\u20138.","journal-title":"Curr Drug Deliver"},{"issue":"7","key":"654_CR149","doi-asserted-by":"publisher","first-page":"629","DOI":"10.2217\/rme-2016-0032","volume":"11","author":"S Misra","year":"2016","unstructured":"Misra S, Chopra K, Saikia UN, Sinha VR, Sehgal R, Modi M, et al. Effect of mesenchymal stem cells and galantamine nanoparticles in rat model of Alzheimer\u2019s disease. Regen Med. 2016;11(7):629\u201346.","journal-title":"Regen Med"},{"issue":"8","key":"654_CR150","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.3109\/10717544.2016.1153748","volume":"23","author":"AS Hanafy","year":"2016","unstructured":"Hanafy AS, Farid RM, Helmy MW, ElGamal SS. Pharmacological, toxicological and neuronal localization assessment of galantamine\/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer\u2019s disease management. Drug Deliver. 2016;23(8):3111\u201322.","journal-title":"Drug Deliver"},{"issue":"2","key":"654_CR151","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jconrel.2010.11.013","volume":"150","author":"G Mittal","year":"2011","unstructured":"Mittal G, Carswell H, Brett R, Currie S, Kumar MN. Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer\u2019s pathology. J Control Release. 2011;150(2):220\u20138.","journal-title":"J Control Release"},{"issue":"1","key":"654_CR152","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40659-016-0093-4","volume":"49","author":"X Cao","year":"2016","unstructured":"Cao X, Hou D, Wang L, Li S, Sun S, Ping Q, et al. Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats. Biol Res. 2016;49(1):32.","journal-title":"Biol Res"},{"issue":"6","key":"654_CR153","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/10837450.2020.1740257","volume":"25","author":"S Arisoy","year":"2020","unstructured":"Arisoy S, Sayiner O, Comoglu T, Onal D, Atalay O, Pehlivanoglu B. In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery. Pharm Dev Technol. 2020;25(6):735\u201347.","journal-title":"Pharm Dev Technol"},{"key":"654_CR154","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.actbio.2020.03.021","volume":"109","author":"LB Vong","year":"2020","unstructured":"Vong LB, Sato Y, Chonpathompikunlert P, Tanasawet S, Hutamekalin P, Nagasaki Y. Self-assembled polydopamine nanoparticles improve treatment in Parkinson\u2019s disease model mice and suppress dopamine-induced dyskinesia. Acta Biomater. 2020;109:220\u20138.","journal-title":"Acta Biomater"},{"key":"654_CR155","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/IJN.S151475","volume":"13","author":"X Yan","year":"2018","unstructured":"Yan X, Xu L, Bi C, Duan D, Chu L, Yu X, et al. Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS\/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects. Int J Nanomed. 2018;13:273\u201381.","journal-title":"Int J Nanomed"},{"key":"654_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119148","volume":"579","author":"SK Bhattamisra","year":"2020","unstructured":"Bhattamisra SK, Shak AT, Xi LW, Safian NH, Choudhury H, Lim WM, et al. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson\u2019s disease. Int J Pharm. 2020;579: 119148.","journal-title":"Int J Pharm"},{"issue":"8","key":"654_CR157","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1016\/j.nano.2018.08.004","volume":"14","author":"V Sridhar","year":"2018","unstructured":"Sridhar V, Gaud R, Bajaj A, Wairkar S. Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson\u2019s disease. Nanomed Nanotechnol Biol Med. 2018;14(8):2609\u201318.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"23","key":"654_CR158","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.2174\/1381612822666160928145346","volume":"23","author":"S Negro","year":"2017","unstructured":"Negro S, Boeva L, Slowing K, Fernandez-Carballido A, Garcia-Garc\u00eda L, Barcia E. Efficacy of ropinirole-loaded PLGA microspheres for the reversion of rotenone- induced Parkinsonism. Curr Pharm Des. 2017;23(23):3423\u201331.","journal-title":"Curr Pharm Des"},{"key":"654_CR159","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijbiomac.2017.12.056","volume":"109","author":"R Raj","year":"2018","unstructured":"Raj R, Wairkar S, Sridhar V, Gaud R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: development, characterization and in vivo anti-Parkinson activity. Int J Biol Macromol. 2018;109:27\u201335.","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"654_CR160","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ejps.2012.12.007","volume":"48","author":"S Md","year":"2013","unstructured":"Md S, Khan RA, Mustafa G, Chuttani K, Baboota S, Sahni JK, et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci. 2013;48(3):393\u2013405.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"654_CR161","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1158\/1535-7163.MCT-18-1250","volume":"18","author":"A Renziehausen","year":"2019","unstructured":"Renziehausen A, Tsiailanis AD, Perryman R, Stylos EK, Chatzigiannis C, O\u2019Neill K, et al. Encapsulation of temozolomide in a calixarene nanocapsule improves its stability and enhances its therapeutic efficacy against glioblastoma. Mol Cancer Ther. 2019;18(9):1497\u2013505.","journal-title":"Mol Cancer Ther"},{"key":"654_CR162","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jconrel.2019.07.015","volume":"309","author":"M Zhao","year":"2019","unstructured":"Zhao M, Bozzato E, Joudiou N, Ghiassinejad S, Danhier F, Gallez B, et al. Codelivery of paclitaxel and temozolomide through a photopolymerizable hydrogel prevents glioblastoma recurrence after surgical resection. J Control Release. 2019;309:72\u201381.","journal-title":"J Control Release"},{"issue":"12","key":"654_CR163","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1039\/c1nr10797f","volume":"3","author":"MA Malvindi","year":"2011","unstructured":"Malvindi MA, Di Corato R, Curcio A, Melisi D, Rimoli MG, Tortiglione C, et al. Multiple functionalization of fluorescent nanoparticles for specific biolabeling and drug delivery of dopamine. Nanoscale. 2011;3(12):5110\u20139.","journal-title":"Nanoscale"},{"issue":"7","key":"654_CR164","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3109\/03639045.2013.789051","volume":"40","author":"S Sharma","year":"2014","unstructured":"Sharma S, Lohan S, Murthy RS. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm. 2014;40(7):869\u201378.","journal-title":"Drug Dev Ind Pharm"},{"key":"654_CR165","doi-asserted-by":"crossref","unstructured":"Ahmad MZ, Sabri AHB, Anjani QK, Dom\u00ednguez-Robles J, Abdul Latip N, Hamid KA. Design and Development of Levodopa Loaded Polymeric Nanoparticles for Intranasal Delivery. Pharmaceuticals (Basel). 2022 Mar 18;15(3):370.\u00a0 https:\/\/doi.org\/10.3390\/ph15030370.","DOI":"10.3390\/ph15030370"},{"issue":"3","key":"654_CR166","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5607\/en.2014.23.3.246","volume":"23","author":"PY Gambaryan","year":"2014","unstructured":"Gambaryan PY, Kondrasheva IG, Severin ES, Guseva AA, Kamensky AA. Increasing the efficiency of Parkinson\u2019s disease treatment using a poly(lactic-co-glycolic acid) (PLGA) based L-DOPA delivery system. Exp Neurobiol. 2014;23(3):246\u201352.","journal-title":"Exp Neurobiol."},{"issue":"7","key":"654_CR167","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.drudis.2015.02.009","volume":"20","author":"G Leyva-G\u00f3mez","year":"2015","unstructured":"Leyva-G\u00f3mez G, Cort\u00e9s H, Maga\u00f1a JJ, Leyva-Garc\u00eda N, Quintanar-Guerrero D, Flor\u00e1n B. Nanoparticle technology for treatment of Parkinson\u2019s disease: the role of surface phenomena in reaching the brain. Drug Discovery Today. 2015;20(7):824\u201337.","journal-title":"Drug Discovery Today"},{"issue":"9","key":"654_CR168","doi-asserted-by":"publisher","first-page":"6194","DOI":"10.3390\/ijms12096194","volume":"12","author":"NC Ngwuluka","year":"2011","unstructured":"Ngwuluka NC, Pillay V, Choonara YE, Modi G, Naidoo D, du Toit LC, et al. Fabrication, modeling and characterization of multi-crosslinked methacrylate copolymeric nanoparticles for oral drug delivery. Int J Mol Sci. 2011;12(9):6194\u2013225.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"654_CR169","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ejpb.2011.10.015","volume":"80","author":"E Esposito","year":"2012","unstructured":"Esposito E, Mariani P, Ravani L, Contado C, Volta M, Bido S, et al. Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. Eur J Pharm Biopharm. 2012;80(2):306\u201314.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"654_CR170","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jps.22285","volume":"100","author":"MJ Tsai","year":"2011","unstructured":"Tsai MJ, Huang YB, Wu PC, Fu YS, Kao YR, Fang JY, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci. 2011;100(2):547\u201357.","journal-title":"J Pharm Sci"},{"key":"654_CR171","first-page":"1599","volume":"7","author":"CJ Wen","year":"2012","unstructured":"Wen CJ, Zhang LW, Al-Suwayeh SA, Yen TC, Fang JY. Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomed. 2012;7:1599\u2013611.","journal-title":"Int J Nanomed"},{"issue":"40","key":"654_CR172","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/21\/40\/405101","volume":"21","author":"SH Hsu","year":"2010","unstructured":"Hsu SH, Wen CJ, Al-Suwayeh SA, Chang HW, Yen TC, Fang JY. Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: Apomorphine as a model drug. Nanotechnology. 2010;21(40): 405101.","journal-title":"Nanotechnology"},{"issue":"9","key":"654_CR173","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/jgm.1361","volume":"11","author":"R Huang","year":"2009","unstructured":"Huang R, Han L, Li J, Ren F, Ke W, Jiang C, et al. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med. 2009;11(9):754\u201363.","journal-title":"J Gene Med"},{"issue":"7","key":"654_CR174","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.nano.2012.02.009","volume":"8","author":"D Martinez-Fong","year":"2012","unstructured":"Martinez-Fong D, Bannon MJ, Trudeau LE, Gonzalez-Barrios JA, Arango-Rodriguez ML, Hernandez-Chan NG, et al. NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson\u2019s disease. Nanomedicine. 2012;8(7):1052\u201369.","journal-title":"Nanomedicine"}],"updated-by":[{"DOI":"10.1007\/s40291-023-00682-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000}}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-023-00654-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-023-00654-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-023-00654-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T14:35:17Z","timestamp":1698330917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-023-00654-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":174,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["654"],"URL":"https:\/\/doi.org\/10.1007\/s40291-023-00654-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40291-023-00682-x","asserted-by":"object"}]},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"30 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40291-023-00682-x","URL":"https:\/\/doi.org\/10.1007\/s40291-023-00682-x","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thuy Trang Nguyen, Phuong-Trang Nguyen-Thi, Thi Hong Anh Nguyen, Thanh Tam Ho, Nguyen-Minh-An Tran, Toi Van Vo, and Giau Van Vo declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This study is partially funded by the Vietnam National University Ho Chi Minh City (VNU-HCM) under grant\/award number NCM2020-28-01 (to VVT).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Thuy Trang Nguyen: conceptualization, data curation, methodology, writing\u2014original draft preparation, and visualization; Phuong-Trang Nguyen-Thi, Thi Hong Anh Nguyen, Nguyen-Minh-An Tran: conceptualization, methodology, writing\u2014reviewing; Toi Van Vo: conceptualization, methodology, supervision, and editing; Thanh-Tam Ho and Giau Van Vo: formal analysis, investigation, resources, data curation, writing of original draft, visualization, and writing of final paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"All data generated or analyzed during this study is available and can be provided if required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participate and publication)"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}